{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670320057614336.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.4049/jimmunol.167.6.3201"}},{"identifier":{"@type":"URI","@value":"https://academic.oup.com/jimmunol/article-pdf/167/6/3201/62543518/3201.pdf"}}],"dc:title":[{"@value":"Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title>\n                  <jats:p>Wild-type ErbB-2 (E2) positive D2F2/E2 tumors are rejected by active vaccination with ErbB-2 DNA. However, anti-ErbB-2 Ab response can cause cardiac toxicity or interfere with cellular immunity. It will be advantageous to induce only cellular immunity by active vaccination. A panel of E2 DNA vaccines were constructed, and their vaccination efficacy was ranked as E2 &gt; tyrosine kinase-deficient ErbB-2 (E2A) &gt; full-length ErbB-2 targeted to the cytoplasm (cytE2) &gt; tyrosine kinase-deficient cytE2 (cytE2A). E2A is a tyrosine kinase-deficient mutant containing a single residue substitution. CytE2 or cytE2A encodes a full-length protein that is targeted to and rapidly degraded in the cytosol by the proteasomes. Covaccination with cytE2A and GM-CSF or IL-2 DNA resulted in equivalent anti-tumor activity as E2. However, anti-ErbB-2 Ab was induced by E2 or E2A, but not cytE2 or cytE2A. Therefore, cytE2A appears to induce anti-tumor immunity without an Ab response. ErbB-2-specific CTL were detected in mice immunized with cytE2A and GM-CSF and have rejected tumor challenge. Depletion of CD8, but not CD4 T cells reduced anti-tumor immunity, indicating CTL as the effector cells. Covaccination with E2A and cytE2A induced synergistic anti-tumor activity, supporting enhanced peptide presentation from cytE2A, which was further evidenced by superior CTL activation using APCs expressing cytE2 vs E2. Taken together, cytoplasmic ErbB-2 DNA induced anti-tumor CTL, but not humoral response, demonstrating the feasibility of eliciting individual effector mechanism by targeted DNA vaccine.</jats:p>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380589016249482753","@type":"Researcher","foaf:name":[{"@value":"Shari A Pilon"}],"jpcoar:affiliationName":[{"@value":"Department of Immunology and Microbiology, Wayne State University , Detroit, MI 48201"}]},{"@id":"https://cir.nii.ac.jp/crid/1380589016249482752","@type":"Researcher","foaf:name":[{"@value":"Marie P Piechocki"}],"jpcoar:affiliationName":[{"@value":"Karmanos Cancer Institute, Wayne State University , Detroit, MI 48201"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670320057614336","@type":"Researcher","foaf:name":[{"@value":"Wei-Zen Wei"}],"jpcoar:affiliationName":[{"@value":"Department of Immunology and Microbiology, Wayne State University , Detroit, MI 48201"},{"@value":"Karmanos Cancer Institute, Wayne State University , Detroit, MI 48201"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00221767"},{"@type":"EISSN","@value":"15506606"}],"prism:publicationName":[{"@value":"The Journal of Immunology"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2001-09","prism:volume":"167","prism:number":"6","prism:startingPage":"3201","prism:endingPage":"3206"},"reviewed":"false","dc:rights":["https://academic.oup.com/pages/standard-publication-reuse-rights"],"url":[{"@id":"https://academic.oup.com/jimmunol/article-pdf/167/6/3201/62543518/3201.pdf"}],"createdAt":"2014-04-20","modifiedAt":"2026-02-02","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360565168638314880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Redirecting Gene-Modified T Cells toward Various Cancer Types Using Tagged Antibodies"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.4049/jimmunol.167.6.3201"},{"@type":"CROSSREF","@value":"10.1158/1078-0432.ccr-12-1449_references_DOI_AJxYa4Xi4rm2IJp78fUDiFPMPO2"}]}